<DOC>
	<DOCNO>NCT00562640</DOCNO>
	<brief_summary>RATIONALE : Giving colony-stimulating factor , G-CSF , help stem cell move bone marrow blood collect . Treating stem cell collect patient 's blood laboratory may increase number immune cell mount immune response tumor . The treated stem cell may help destroy remain tumor cell ( graft-versus-tumor effect ) . Chemotherapy may also give patient prepare bone marrow stem cell transplant . PURPOSE : This phase I trial study side effect best dose autologous T cell give without cyclophosphamide fludarabine treat patient recurrent persistent advanced ovarian epithelial cancer , primary peritoneal cavity cancer , fallopian tube cancer . ( fludarabine treatment close 12/012009 )</brief_summary>
	<brief_title>Autologous T Cells With Without Cyclophosphamide Fludarabine Treating Patients With Recurrent Persistent Advanced Ovarian Epithelial Cancer , Primary Peritoneal Cavity Cancer , Fallopian Tube Cancer ( Fludarabine Treatment Closed 12/01/2009 )</brief_title>
	<detailed_description>OBJECTIVES : - To assess safety tolerability vitro expand autologous WT1 specific T cell , administer alone combination non-myeloablative , immunosuppressive conditioning , patient recurrent persistent , advanced , WT1-positive , ovarian epithelial cancer , primary peritoneal cavity cancer , fallopian tube cancer . - To determine maximum tolerate dose autologous WT1 specific T cell patient . - To quantitate alteration concentration WT1 specific T cell blood define interval post infusion without non-myeloablative , immunosuppressive conditioning order gain estimate regard survival proliferation . - To assess effect adoptively transfer T cell growth progression advance ovarian epithelial cancer , primary peritoneal cavity cancer , fallopian tube cancer . OUTLINE : This dose-escalation study WT1 peptide-specific T cell . - T-cell generation isolation : Patients undergo collection peripheral blood stem cell ( PBMC ) T cell purify , stimulate vitro WT1 peptide-pulsed autologous EBV BLCL , expand ex vivo . - Stem cell mobilization harvest : Patients receive filgrastim ( G-CSF ) subcutaneously daily five day . PBMC collect leukapheresis fifth day cryopreserved subsequent reinfusion patient , event prolong cytopenia . - Autologous T-cell infusion without condition chemotherapy ( fludarabine treatment close 12/01/2009 ) : Approximately 4-6 week T-cell sensitization , patient receive infusion autologous WT1-specific T cell 5-10 minute day 0 . Patients enrol dose level II III also undergo pre-infusion lymphodepletive conditioning comprise cyclophosphamide IV day -2 fludarabine phosphate IV approximately 30 minute day -6 -2 . After 48-hour rest period , patient receive autologous WT1-specific T cell . Treatment repeat every 14 day 4 course absence disease progression unacceptable toxicity . Patients responsive stable disease completion therapy , may receive additional course autologous WT1-specific T cell every 14 day . Blood sample obtain baseline periodically study assayed alteration circulate level WT1 peptide-specific T cell , biochemical index tumor burden , radiologic evidence tumor response . Serum CA125 level measure number T cell generate interferon gamma response autologous EBV BLCL quantitated . After completion study therapy , patient follow 12 week .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologically confirm ovarian epithelial carcinoma , primary peritoneal cavity carcinoma , fallopian tube carcinoma Recurrent persistent disease treatment platinumbased chemotherapy Must platinumresistant intolerant disease Evaluable disease , demonstrate serological ( i.e. , CA 125 ) , radiological , pathological study Tumor must express Wilms Tumor Gene 1 ( WT1 ) peptide , detect IHC analysis bank ( i.e. , paraffinembedded ) freshly biopsied tumor nodules Only WT1 tumor grade moderate strong ( score 412 ) accord adapted German Immunoreactive Score criterion consider positive No prior concurrent brain metastasis PATIENT CHARACTERISTICS : Karnofsky performance status ( PS ) 70100 % OR WHO PS 01 Life expectancy ≥ 6 month ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 60mL/min ALT AST ≤ 2.5 time upper limit normal ( ULN ) Total bilirubin ≤ 1.5 time ULN Adequate pulmonary cardiac function No clinical evidence cardiopulmonary disease , , opinion investigator , would preclude enrollment Able keep schedule visit No known hepatitis B C infection No known HIV positivity No evidence bowel obstruction No clinically significant heart disease ( New York Heart Association class III IV ) No active infection require antibiotic within two week study entry No serious intercurrent illness require hospitalization No history primary secondary immunodeficiency autoimmune disease No cancer except nonmelanomatous skin cancer within past 5 year Not pregnant lactate No issue , opinion treat physician , would make patient ineligible study PRIOR CONCURRENT THERAPY : More 3 week since prior anticancer therapy ( i.e. , chemotherapy , biologic therapy , immunotherapy ) No history whole abdominal radiation therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent primary peritoneal cavity cancer</keyword>
	<keyword>stage IIIA primary peritoneal cavity cancer</keyword>
	<keyword>stage IIIB primary peritoneal cavity cancer</keyword>
	<keyword>stage IIIC primary peritoneal cavity cancer</keyword>
	<keyword>stage IV primary peritoneal cavity cancer</keyword>
	<keyword>recurrent fallopian tube cancer</keyword>
	<keyword>stage IIIA fallopian tube cancer</keyword>
	<keyword>stage IIIB fallopian tube cancer</keyword>
	<keyword>stage IIIC fallopian tube cancer</keyword>
	<keyword>stage IV fallopian tube cancer</keyword>
	<keyword>stage IIIA ovarian epithelial cancer</keyword>
	<keyword>stage IIIB ovarian epithelial cancer</keyword>
	<keyword>stage IIIC ovarian epithelial cancer</keyword>
	<keyword>06-155</keyword>
</DOC>